SEC Form 4 · accession 0001209191-18-058641
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Gorlin
Director
Period of report
Nov 12, 2018
Accepted (ET)
Nov 14, 2018 · 8:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 12, 2018 | S | 47,050 | $2.4328 | D | 149,230 | D | |
| Common StockF2 | Nov 13, 2018 | S | 33,300 | $2.399 | D | 115,930 | D | |
| Common StockF3 | Nov 14, 2018 | S | 115,930 | $2.2058 | D | 0 | D | |
| Common Stock | holding | — | — | — | 321,720 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average share price of an aggregate total of 47,050 shares sold in the price range of $2.40 to $2.62 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average share price of an aggregate total of 33,300 shares sold in the price range of $2.38 to $2.47 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average share price of an aggregate total of 115,930 shares sold in the price range of $2.17 to $2.40 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.